GSK3A(GSK3a)
Sign in to save this workspaceUniProt P49840 · PDB · AlphaFold · Substrate: Phospho-Glycogen Synthase peptide · Clone: full lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 97.2% | 2.8% | 91.48 | 0.563 |
| 2 | Defactinib | 84.1% | 15.9% | 92.68 | 0.450 |
| 3 | Pacritinib | 67.4% | 32.6% | 88.64 | 0.452 |
| 4 | Midostaurin | 60.7% | 39.3% | 78.64 | 0.500 |
| 5 | Vemurafenib | 46.0% | 54.0% | 96.49 | 0.598 |
| 6 | Encorafenib | 44.8% | 55.2% | 98.50 | 0.755 |
| 7 | Pralsetinib | 42.0% | 58.0% | 93.43 | 0.643 |
| 8 | Darovasertib | 36.4% | 63.6% | 96.99 | 0.719 |
| 9 | Dabrafenib | 31.7% | 68.3% | 94.74 | 0.633 |
| 10 | Neratinib | 30.5% | 69.5% | 93.18 | 0.597 |
| 11 | Gefitinib | 27.9% | 72.1% | 99.25 | 0.650 |
| 12 | Dacomitinib | 27.5% | 72.5% | 97.99 | 0.664 |
| 13 | Nintedanib | 26.8% | 73.2% | 90.23 | 0.608 |
| 14 | Fostamatinib | 25.7% | 74.3% | 96.74 | 0.613 |
| 15 | Imatinib | 25.0% | 75.0% | 99.00 | 0.718 |
| 16 | Baricitinib | 24.0% | 76.0% | 97.99 | 0.616 |
| 17 | Deucravacitinib | 22.8% | 77.2% | 98.99 | 0.718 |
| 18 | Sirolimus | 22.3% | 77.7% | 100.00 | 0.708 |
| 19 | Trametinib | 21.5% | 78.5% | 99.50 | 0.718 |
| 20 | Everolimus | 21.5% | 78.5% | 100.00 | 0.706 |
Paralog block
GSK3A, GSK3B
EMT expression
- Mesenchymal log2(TPM+1): 5.41
- Epithelial log2(TPM+1): 5.50
- Fold change: -0.08
- Status: No significant change
High-confidence drugs
- Abemaciclib — inh 97.2% · KISS 34.39
- Defactinib — inh 84.1% · KISS 15.08
- Pacritinib — inh 67.4% · KISS -3.48
Selectivity landscape vs inhibition on GSK3A
Each point is one of the 92 approved drugs; color = inhibition % on GSK3A.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…